NCT05246670: Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial

NCT05246670
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be experiencing pain, numbness, tingling or other symptoms of chemotherapy-induced peripheral neuropathy for more than 3 months (90 days)
Exclusions: 
https://ClinicalTrials.gov/show/NCT05246670

Comments are closed.

Up ↑